NVS vs VERA: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
NVS is the larger of the two ($286.41B market cap): the incumbent the market prices for continued execution (15.27x forward earnings, beta 0.45). VERA is the smaller challenger ($1.85B), still expected to post a loss next year: more room to run, but more to prove. If you believe in growth, VERA fits: analysts expect its revenue to rise 726% next year, against 7% for NVS. If you believe in profit, NVS fits: it is expected to make money next year (15.27x forward earnings), while VERA is still expected to post a loss.
NVS vs VERA: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | NVS | VERA | What it tells you |
|---|---|---|---|
| Market cap | $286.41B | $1.85B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 15.27 | -6.54 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.45 | 1.19 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 58% of range | 2% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 7.69 | 5.55 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how NVS and VERA affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NVS and VERA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NVS and VERA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Novartis AG (NVS) do?
Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Over the past several years it deliberately reshaped itself into a pure-play innovative-medicines business: it spun off the Alcon eye-care division in 2019 and separated the Sandoz generics and biosimilars unit in 2023, distributing those shares to Novartis holders. What remains is a focused portfolio of patented prescription drugs concentrated in four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. Oncology is its largest contributor, and the company has built a reputation for high core operating margins, reaching roughly 40% in 2025. Revenue was about $56.7 billion in 2025, roughly 10% above 2024, and trailing twelve-month revenue is about $57.4 billion with net income near $10.0 billion.
What does Vera Therapeutics (VERA) do?
Vera Therapeutics is a biotechnology company focused on autoimmune kidney disease. Its lead asset is atacicept (brand name TRUTAKNA, atacicept-vymj), a subcutaneous fusion protein that blocks two B-cell signaling proteins, BAFF and APRIL, which drive the antibody production behind IgA nephropathy (IgAN), a progressive disease that can lead to kidney failure. In the ORIGIN Phase 3 trial, atacicept cut proteinuria (protein leaking into urine, a key marker of kidney damage) by about 46% from baseline and roughly 42% versus placebo at 36 weeks, and on July 7, 2026 the FDA granted accelerated approval, making it the first dual BAFF/APRIL inhibitor cleared for IgAN. In mid-September 2026 Vera reported that the final ORIGIN 3 analysis met all its Phase 3 endpoints: eGFR fell by only about 0.1 mL/min/1.73m2 at 52 weeks on TRUTAKNA versus about 5.7 on placebo, the annualised eGFR decline through 104 weeks was about 0.6 versus 5.6, and there were 11 kidney-progression events versus 38 on placebo. The full results were presented as a late-breaking oral at the opening plenary of ASN Kidney Week 2026, with a simultaneous New England Journal of Medicine publication, and Vera reported a 76% reduction in the risk of composite kidney-disease progression versus placebo through two years. On November 3, 2026 Vera submitted a supplemental BLA for full approval, which it expects in mid-2027, and it plans a European marketing application in the first quarter of 2027.
NVS vs VERA: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- NVS drivers: Priority growth brands offsetting the cliff; Focused, high-margin innovative-medicines model.
- VERA drivers: TRUTAKNA commercial launch; Full approval and eGFR data.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed. For VERA, vera has only one quarter of product revenue (about $10.3 million) and funds itself through large operating losses, so it depends on its cash balance (about $384 million at September 30, 2026, or about $459 million pro forma for an October debt draw, against a trailing net loss of about $415 million and nine-month operating cash burn of about $306 million) and capital markets to reach sustained profitability.
NVS or VERA: which should you pick?
If the story you believe is NVS's (Priority growth brands offsetting the cliff), NVS is the more direct way to own it; if it is VERA's (TRUTAKNA commercial launch), VERA is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NVS and VERA guides.
NVS vs VERA: the full fundamentals
NVS. At about $152, NVS trades near 29 times trailing earnings but only about 15 times forward estimates, a gap that widened after a third quarter in which reported profit fell to about $1.2 billion while core EPS beat. Analysts expect EPS of about $9.07 in 2026 and $9.93 in 2027. The analyst mean target of roughly $157 sits close to the current price, so how fast the growth brands keep absorbing the generic erosion, and the run of pipeline readouts into 2027, matter more than any single trailing figure. Figures are approximate and tied to the asOf date; verify live numbers before acting.
VERA. As of November 2026, Vera's valuation reflects expectations for atacicept sales rather than current financials: the first launch quarter brought about $10.3 million of revenue against a net loss of about $93.7 million. Its roughly $459 million of pro forma cash, plus further debt capacity, funds the TRUTAKNA launch, though the loss rate shows the runway is finite. Any earnings multiple is not meaningful until commercial revenue builds; at about $1.85 billion the market value sits near 7x the ~$258 million of 2027 revenue analysts expect.
Headline figures (approximate, November 2026): NVS shows revenue (ttm) ~$57.4B; Q3 2026 revenue ~$15.03B, up ~5% year over year, growth drivers Priority brands Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix offsetting Entresto's generic decline, margins (ttm) ~75% gross, ~34% operating, ~17.5% net, net income (ttm) ~$10.0B; VERA shows revenue (ttm) ~$10.3M (first TRUTAKNA sales, Q3 2026), net loss (q3 2026) ~$93.7M, net loss per share (q3 2026) ~$1.30 (vs ~$1.62 expected), net loss (ttm) ~$415M.
The bottom line: NVS vs VERA
NVS and VERA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined NVS and VERA exposure against your real portfolio. It is not an investment adviser.
Wondering how NVS or VERA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Novartis AG
Ask Walnut's AI anything about NVS and see how it fits what you own.
FAQ
What is the difference between NVS and VERA?
+
Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Vera Therapeutics is a biotechnology company focused on autoimmune kidney disease. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is NVS or VERA the better stock?
+
Neither is universally better. NVS is the larger incumbent; VERA is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, NVS or VERA?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both NVS and VERA?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of NVS vs VERA?
+
NVS: The dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed. Analysts expect 2026 EPS to be about flat before rising about 10% in 2027, and reported earnings fell about 69% year over year in the latest quarter. Pipeline risk is structural because late-stage trials can fail and regulators can reject or delay approvals, turning expected future revenue into a write-off, as pelacarsen's failed HORIZON outcomes trial did in 2026. Large acquisitions such as Avidity add integration and financing risk and raised debt, which stood at about $48 billion against about $8.9 billion of cash at September 30, 2026. US drug-pricing policy, potential pharmaceutical tariffs, and pricing pressure are outside the company's control and could compress margins, and in November 2026 the CEO warned that US limits on investment in Chinese biotech could hurt drug development. Because NVS is a Swiss ADR, US investors also carry dollar-versus-Swiss-franc currency risk, and Swiss dividend withholding tax reduces net income for some holders. Concentration in a handful of growth drugs means a single clinical or commercial setback can move the stock. VERA: Vera has only one quarter of product revenue (about $10.3 million) and funds itself through large operating losses, so it depends on its cash balance (about $384 million at September 30, 2026, or about $459 million pro forma for an October debt draw, against a trailing net loss of about $415 million and nine-month operating cash burn of about $306 million) and capital markets to reach sustained profitability. The IgAN market is already crowded, with atacicept arriving as roughly the sixth approved drug alongside offerings from Novartis, Travere, Otsuka and others, which pressures pricing and share. Vertex's povetacicept, another dual BAFF/APRIL inhibitor whose Phase 3 RAINER trial met its primary endpoint, removes the first-in-class mechanism advantage once it reaches market. The confirmatory eGFR data came in positive in September 2026, but the label stays conditional until the FDA acts on the full-approval filing submitted November 3, with a decision expected in mid-2027. Borrowing under its debt facility adds interest costs and covenants. As a largely single-product company, the stock is highly sensitive to launch execution, competitive dynamics, and safety signals, and its valuation already prices in significant commercial success. The share price has already shown this sensitivity: VERA fell about 47% in 2026 through November 20, reversed lower on the day of its positive ORIGIN 3 news, and kept falling after a Q3 revenue beat; in October 2026 BofA cut its target to $60 from $66 and Leerink initiated at market perform with a $34 target, and in November Wedbush cut its target to $29 from $34.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell NVS or VERA; figures are approximate and dated (as of November 2026). Verify current data before investing.